Swiss drug giant Novartis and Belgian pharma company UCB announced a deal to co-develop and commercialize two products targeting Parkinson’s disease, UCB0599 and UCB7853.
If you are not happy with the results below please do another search
50 search results for:
Vincent Colicchio – Vice President, Supply Chain and External Manufacturing for Dr. Reddy’s Laboratories – discusses supply chain, manufacturing and training issues pertaining to generic drug manufacturing.
Real Chemistry, a leading provider of data-driven, tech-enabled communication and marketing solutions for the health care sector, announced Founder and Chief Executive Officer Jim Weiss will become chairman and Shankar Narayanan will become chief executive officer and a member of the board of directors effective January 3, 2022. In addition to his role as chairman and founder of Real Chemistry, Weiss will join New Mountain Capital (NMC), Real Chemistry’s investment partner, as an executive advisor.
Germany decided on December 2 to bar the unvaccinated from all but the most essential business and the United States prepared further travel restrictions as the world scrambled to curb the Omicron variant of the coronavirus.
Astellas and Dyno Therapeutics announced a research collaboration to develop next-generation adeno-associated virus (AAV) gene therapy vectors for skeletal and cardiac muscle using Dyno’s CapsidMap platform.
Novavax Inc. said on Thursday the company could begin commercial manufacturing of a Covid-19 vaccine tailored for the Omicron coronavirus variant in January 2022, while testing whether or not its current vaccine works against the variant.
A case of the Omicron coronavirus variant was identified in Minnesota on December 2, the U.S. state’s health department said, with the identification coming a day after the United States reported the country’s first case of the new variant.
Amgen’s oral drug candidate for genital psoriasis delivered positive topline results from a Phase III trial, with both primary and secondary endpoints met by Otezla (apremilast).
We are entering a golden age of biomedical diagnostics and personalized treatment. The cost of pharmacogenetic testing continues to decline and more insurers are offering coverage for these tests. This will allow clinicians and medical researchers to really drill down into the data to improve patient outcomes and determine in advance what treatment will work best – and which treatments to avoid – for each individual. It’s an exciting time, according to Jonathan Stein, Chief Scientific Officer at Tesis Biosciences.
Laboratory analysis of the antibody-based Covid-19 therapy GlaxoSmithKline is developing with U.S. partner Vir Biotechnology indicated the drug is effective against the new Omicron variant, the British drugmaker said on December 2.